Trial record 3 of 3227 for:    reach 2

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02435433
Recruitment Status : Recruiting
First Posted : May 6, 2015
Last Update Posted : March 21, 2018
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 2018
  Estimated Study Completion Date : June 2020